<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365777</url>
  </required_header>
  <id_info>
    <org_study_id>ChiECRCT20200002</org_study_id>
    <nct_id>NCT04365777</nct_id>
  </id_info>
  <brief_title>EEG Characteristics of Different Sedation Depths in Neurosurgery Patients</brief_title>
  <official_title>EEG Characteristics of Different Sedation Depths in Patients With Supratentorial Glioma in Frontal Lobe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gliomas are the most common primary intracranial malignancy, and behavioral experiments in&#xD;
      patients with supratentorial gliomas under sedation have shown potential neurological&#xD;
      abnormalities; however, these behavioral experiments are susceptible to external influences.&#xD;
      Therefore, more objective evidence is needed to support and extend the existing conclusions.&#xD;
      The purpose of this study is to compare the EEG signatures (such as the EEG signal power) at&#xD;
      various levels of anesthetics induced sedation in patients with supratentorial glioma in&#xD;
      frontal lobe and in patients without intracranial-occupying lesion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">February 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. The time-frequency characteristics of EEG power changes at different sedation depths in neurosurgical patients.</measure>
    <time_frame>Prior to anesthesia induction, three minutes after reaching the target level of sedation</time_frame>
    <description>The EEG power will be calculated by raw signal at awake, eye-closed state and after reaching the steady-state sedation depths of OAA/S=3 and OAA/S=1.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Electroencephalography</condition>
  <arm_group>
    <arm_group_label>Awake group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild sedation group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep sedation group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OAA/S=5</intervention_name>
    <description>Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.</description>
    <arm_group_label>Awake group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OAA/S=3</intervention_name>
    <description>Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.</description>
    <arm_group_label>Mild sedation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OAA/S=1</intervention_name>
    <description>Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.</description>
    <arm_group_label>Deep sedation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged between 18 and 60 years with American Society of Anesthesiology status I or&#xD;
        II who were scheduled to receive elective surgery under general anesthesia. Patients with&#xD;
        supratentorial glioma in right frontal lobe diagnosed by magnetic resonance imaging were&#xD;
        included in the glioma group while patients requiring general anesthesia without&#xD;
        intracranial-occupying lesion were included in the control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with supratentorial glioma in right frontal lobe, and patients requiring&#xD;
             general anesthesia without intracranial-occupying lesion;&#xD;
&#xD;
          2. Aged 18-60 years;&#xD;
&#xD;
          3. ASA I to II;&#xD;
&#xD;
          4. All those who sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Obese patients, BMI&gt;30kg/m2;&#xD;
&#xD;
          2. Patients with Mallampati class III to IV airway anatomy;&#xD;
&#xD;
          3. Combined with other neurological or psychiatric diseases;&#xD;
&#xD;
          4. Combined with disturbance of consciousness;&#xD;
&#xD;
          5. Previous intracranial surgery;&#xD;
&#xD;
          6. Known or suspected cardiac dysfunction;&#xD;
&#xD;
          7. Allergic to intravenous general anesthetics;&#xD;
&#xD;
          8. Long-term history of analgesia, sedation and drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing TianTan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

